Bladder Cancer

From the Desk of the Editor

It is with great pleasure that I welcome you to the Center of Excellence on Bladder Cancer. “The time is now”. This is an often used phrase in literature, often enough to be considered a cliché. Yet it is exactly this term which applies to the field of bladder cancer research today.

After decades of relative stagnation our field is moving at a dizzying pace toward meaningful improvements in patient care for those suffering from this disease. From better understanding of variant histology, knowledge of the genetic profile of tumors, identification of key signaling pathways, advances in immunotherapy, the adoption of enhanced recover pathways, and more, we now have the tools to make truly meaningful improvements in our patients’ outcomes.
Read more ...

TURBT More Important Than Ever

Non-muscle invasive bladder cancer (NMIBC) will account for 75% of the 79,000 new cases of bladder cancer expected to be diagnosed in 2017. Fortunately most cases can be successfully treated and carry a relatively good prognosis. However, depending on the grade and stage at initial diagnosis, as many as 60% of patients with NMIBC can experience orthotopic tumor recurrence within the first year after initial resection and up to 78% can recur within five years. 
Read more ...

EAU 2017: State-of-the-art Lecture: Biomarkers for Treatment Selection

London, England (UroToday.com) Dr. Shahrokh Shariat delivered a presentation on biomarkers for patient selection, starting the bladder urothelial carcinoma sub-session of the “Immuno-Oncology” session at the EAU 2017.
Read more ...

Merck’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early

TRUCKEE, CA.-Merck today announced that the phase 3 KEYNOTE-045 trial investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS).
Read more ...

Disseminated BCG: Complications of intravesical bladder cancer treatment - Abstract

Intravesical bacillus Calmette-Guerin (BCG) has been established as an effective treatment of superficial bladder cancer (Parker and Kommu, 2013).

Read more ...